NEW YORK, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Immunomedics, Inc. IMMU
Class Period: February 8, 2018 - January 18, 2019
Lead Plaintiff Deadline: February 25, 2019
Join the action: https://www.zlk.com/pslra-1/immunomedics-inc-loss-form?wire=3
The lawsuit alleges: Immunomedics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Immunomedics' Morris Plains, New Jersey drug substance manufacturing facility was not in compliance with FDA requirements; (ii) the Company's Quality Control Unit did not possess the authority to investigate and correct critical FDA violations occurring at the Morris Plains, New Jersey facility; (iii) the Company suffered a February 2018 data integrity breach at the Morris Plains, New Jersey facility which, among other issues, included the backdating records and manipulation of bioburden samples; (iv) the Company's Chemistry, Manufacturing and Control data submitted in connection with its BLA for sacituzumab govitecan was insufficient to support FDA approval; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times
To learn more about the Immunomedics, Inc. class action contact jlevi@levikorsinsky.com.
Alkermes plc ALKS
Class Period: February 17, 2017 - November 1, 2018
Lead Plaintiff Deadline: February 25, 2019
Join the action: https://www.zlk.com/pslra-1/alkermes-plc-loss-form?wire=3
The lawsuit alleges: Alkermes plc made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) the FDA had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for its drug ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes' public statements were materially false and/or misleading at all relevant times.
To learn more about the Alkermes plc class action contact jlevi@levikorsinsky.com.
Uxin Limited UXIN
Class Period: Pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the June 27, 2018 initial public offering
Lead Plaintiff Deadline: April 12, 2019
Join the action: https://www.zlk.com/pslra-1/uxin-limited-loss-form?wire=3
The Registration Statement was materially false and misleading and omitted to state that: (1) Uxin was likely to stop providing complementary services such as inspections to its customers; (2) instead, Uxin would connect consumers to dealers who would provide such complementary services; (3) as a result, Uxin's 2B business would be materially impacted; and (4) consequently, Defendants' statements in the Registration Statement regarding Uxin's business, operations, and prospects, were materially false and/or misleading.
To learn more about the Uxin Limited class action contact jlevi@levikorsinsky.com.
Avon Products, Inc. AVP
Class Period: August 2, 2016 - August 2, 2017
Lead Plaintiff Deadline: April 15, 2019
Join the action: https://www.zlk.com/pslra-1/avon-products-inc-loss-form?wire=3
In order to inflate its reported revenue and representative growth metric during the Class Period, Avon engaged in an undisclosed scheme whereby it significantly loosened its credit terms in order to recruit new representatives in Brazil, its largest market. Avon did not disclose the changes to its credit terms in Brazil. Avon also failed to increase its allowance for doubtful accounts to account for the changes to its credit terms in Brazil.
To learn more about the Avon Products, Inc. class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.